BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Nivegacetor readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Nivegacetor\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06996730-11329@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20300601
DTEND;VALUE=DATE:20300602
SUMMARY:Nivegacetor: Phase 2/3 readout est. (NCT06996730)
DESCRIPTION:Nivegacetor\, phase 2/3\, Alzheimer's Disease.\nStudy: A Study 
 of Donanemab\, RG6289\, or the Combination of Donanemab and RG6289 in Pres
 enilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Do
 minant Alzheimer's Disease\nEstimated primary completion: 1 June 2030. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/nivegacetor#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06996730
URL:https://assetmemo.bio/drug/nivegacetor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
